Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

bioAffinity Technologies (BIAF) Total Liabilities (2022 - 2025)

bioAffinity Technologies (BIAF) has disclosed Total Liabilities for 4 consecutive years, with $2.6 million as the latest value for Q3 2025.

  • On a quarterly basis, Total Liabilities fell 22.93% to $2.6 million in Q3 2025 year-over-year; TTM through Sep 2025 was $2.6 million, a 22.93% decrease, with the full-year FY2024 number at $3.9 million, up 16.2% from a year prior.
  • Total Liabilities was $2.6 million for Q3 2025 at bioAffinity Technologies, down from $6.9 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $16.8 million in Q2 2022 to a low of $775151.0 in Q2 2023.
  • A 4-year average of $4.7 million and a median of $3.2 million in 2024 define the central range for Total Liabilities.
  • Peak YoY movement for Total Liabilities: plummeted 95.38% in 2023, then skyrocketed 315.83% in 2024.
  • bioAffinity Technologies' Total Liabilities stood at $1.1 million in 2022, then soared by 195.63% to $3.4 million in 2023, then increased by 16.2% to $3.9 million in 2024, then plummeted by 32.4% to $2.6 million in 2025.
  • Per Business Quant, the three most recent readings for BIAF's Total Liabilities are $2.6 million (Q3 2025), $6.9 million (Q2 2025), and $4.1 million (Q1 2025).